Future and Emerging Treatments for Microbial Infections

Orbital Disease: Present Status and Future Challenges

Volumn , Issue , 2005, Pages 45-64

  Chow, Anthony W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249935888     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14216-8     Document Type: Chapter

References (51)

1. 1. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, Kelsey SF. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996; 122(1):1–17.
2. Montan P. Endophthalmitis. Curr Opin Ophthalmol 2001; 12(1):75–81.
3. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995; 113(12):1479–1496.
4. Barza M, Pavan PR, Doft BH, Wisniewski SR, Wilson LA, Han DP, Kelsey SF. Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch Ophthalmol 1997; 115(9):1142–1150.
5. Kunimoto DY, Das T, Sharma S, Jalali S, Majji AB, Gopinathan U, Athmanathan S, Rao TN. Microbiologic spectrum and susceptibility of isolates: Part I. Postoperative endophthalmitis. Am J Ophthalmol 1999; 128(2):240–242.
6. Kunimoto DY, Das T, Sharma S, Jalali S, Majji AB, Gopinathan U, Athmanathan S, Nagaraja Rao T. Micro biologic spectrum and susceptibility of isolates: Part II. Posttraumatic endophthalmitis. Am J Ophthal 1999; 128(2): 242–244.
7. Liesegang TJ. Use of antimicrobials to prevent postoperative infection in patients with cataracts. Curr Opin Ophthalmol 2001; 12(1):68–74.
8. Okhravi N, Adamson P, Lightman S. Use of PCR in endophthalmitis. Ocul Immunol Inflamm 2000; 8(3):189–200.
9. Kalicharan D, Jongebloed WL, Los LI, Worst JG. (An)aerobic bacteria found in secondary-cataract material. A SEM=TEM study. Doc Ophthalmol 1992; 82(1–2):125–133.
10. Busin M, Cusumano A, Spitznas M. Intraocular lens removal from eyes with chronic low-grade endophthalmitis. J Cataract Refract Surg 1995; 21(6):679–684.
11. Hykin PG, Tobal K, McIntyre G, Matheson MM, Towler HM, Lightman SL. The diagnosis of delayed post-operative endophthalmitis by polymerase chain reaction of bacterial DNA in vitreous samples. J Med Microbiol 1994; 40(6): 408–415.
12. Therese KL, Anand AR, Madhavan HN. Polymerase chain reaction in the diagnosis of bacterial endophthalmitis. Br J Ophthalmol 1998; 82(9):1078–1082.
13. Lohmann CP, Linde HJ, Reischl U. Improved detection of microorganisms by polymerase chain reaction in delayed endophthalmitis after cataract surgery. Ophthalmology 2000; 107(6):1047–1051.
14. Okhravi N, Adamson P, Carroll N, Dunlop A, Matheson MM, Towler HM, Lightman S. PCR-based evidence of bacterial involvement in eyes with suspected intraocular infection. Invest Ophthalmol Vis Sci 2000; 41(11):3474–3479.
15. Carroll NM, Jaeger EEM, Choudhury S, Dunlop AAS, Matheson MM, Adamson P, Okhravi N, Lightman S. Detection of and discrimination between gram-positive and gram-negative bacteria in intraocular samples by using nested PCR. J Clin Microbiol 2000; 38(5):1753–1757.
16. Goh SH, Potter S, Wood JO, Hemmingsen SM, Reynolds RP, Chow AW. HSP60 gene sequences as universal targets for microbial species identification: studies with coagulasenegative staphylococci. J Clin Microbiol 1996; 34(4): 818–823.
17. Kwok AY, Chow AW. Phylogenetic study of Staphylococcus and Macrococcus species based on partial hsp60 gene sequences. Int J Syst Evol Microbiol 2003; 53(Pt 1):87–92.
18. Wong RS, Chow AW. Identification of enteric pathogens by heat shock protein 60 kDa (HSP60) gene sequences. FEMS Microbiol Lett 2002; 206(1):107–113.
19. Kwok AY, Wilson JT, Coulthart M, Ng LK, Mutharia L, Chow AW. Phylogenetic study and identification of human pathogenic Vibrio species based on partial hsp60 gene sequences. Can J Microbiol 2002; 48(10):903–910.
20. Doft BH, Barza M. Optimal management of postoperative endophthalmitis and results of the Endophthalmitis Vitrectomy Study. Curr Opin Ophthalmol 1996; 7(3):84–94.
21. Baker AS, Durand M. The endophthalmitis vitrectomy study [letter]. Arch Ophthalmol 1996; 114:1025.
22. Ferencz JR, Assia EI, Diamantstein L, Rubinstein E. Vancomycin concentration in the vitreous after intravenous and intravitreal administration for postoperative endophthalmitis. Arch Ophthalmol 1999; 117(8):1023–1027.
23. Ball P. Future of the quinolones. Semin Respir Infect 2001; 16(3):215–224.
24. Talan DA. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 32(suppl 1): S64–S71.
25. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs 2001; 61(6):747–761.
26. Fiscella RG, Nguyen TK, Cwik MJ, Phillpotts BA, Friedlander SM, Alter DC, Shapiro MJ, Blair NP, Gieser JP. Aqueous and vitreous penetration of levofloxacin after oral administration. Ophthalmology 1999; 106(12):2286–2290.
27. Morlet N, Graham GG, Gatus B, McLachlan AJ, Salonikas C, Naidoo D, Goldberg I, Lam CM. Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis. Antimicrob Agents Chemother 2000; 44(6):1674–1679.
28. Wiechens B, Neumann D, Grammer JB, Pleyer U, Hedderich J, Duncker GI. Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes. Int Ophthalmol 1998; 22(3):133–143.
29. Wiechens B, Grammer JB, Johannsen U, Pleyer U, Hedderich J, Duncker GI. Experimental intravitreal application of ciprofloxacin in rabbits. Ophthalmologica 1999; 213(2):120–128.
30. Gurler B, Ozkul Y, Bitiren M, Karadede S, Gurkan T. A study on the toxicity of intravitreal levofloxacin in rabbits. Curr Eye Res 2002; 24(4):253–262.
31. Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647)—the first ketolide. J Antimicrob Chemother 2003; 51(3):497–511
32. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61(4):525–551.
33. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003; 36(4):473–481.
34. Tally FP, DeBruin MF. Development of daptomycin for grampositive infections. J Antimicrob Chemother 2000; 46(4): 523–526.
35. Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin Investig Drugs 2003; 12(3):379–399.
36. Schaison G, Graninger W, Bouza E. Teicoplanin in the treatment of serious infection. J Chemother 2000; 12(suppl 5): 26–33.
37. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36(5):630–637.
38. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001; 14(6):685–691.
39. Craig WA. Does the dose matter? Clin Infect Dis. 2001 33 Suppl 3:S233–7. S233–S237.
40. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19(4):261–268.
41. Craig WA. Pharmacokinetic=pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26(1):1–10.
42. Naimi TS, LeDell KH, Boxrud DJ, Groom AV, Steward CD, Johnson SK, Besser JM, O’Boyle C, Danila RN, Cheek JE, Osterholm MT, Moore KA, Smith KE. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996–1998. Clin Infect Dis 2001; 33(7):990–996.
43. Hiramatsu K, Okuma K, Ma XX, Yamamoto M, Hori S, Kapi M. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Curr Opin Infect Dis 2002; 15(4):407–413.
44. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev 2002; 15(3):430–438.
45. Conly J. Antimicrobial resistance in Canada. Can Med Assoc J 2002; 167(8):885–891.
46. Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit 1509. Postgrad Med J 2002; 78(921):385–392.
47. Taylor GD, McKenzie M, Kirkland T, Buchanan-Chell M, Wiens R. The impact of health care restructuring on nosocomially acquired blood stream infections. Can J Infect Dis 2000; 11(1):29–32.
48. Health Canada and the Canadian Infectious Disease Society. Controlling antimicrobial resistance: an integrated action plan for Canadians. Can Commun Dis Rep 1997; 23(suppl 7):1–32.
49. Alfonso EC, Flynn HW Jr. Controversies in endophthalmitis prevention. The risk for emerging resistance to vancomycin. Arch Ophthalmol 1995; 113(11):1369–1370.
50. Center for Disease Control. Recommendations for preventing the spread vancomycin resistance recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Morb Mort Wkly Rep 1995; 44:1–13.
51. AAO-CDC Task Force. The prophylactic use of vancomycin for intraocular surgery. A joint statement of the American Academy of Ophthalmology and the Centers for Disease Control and Prevention. Quality of care Publications, No. 515, American Academy of Ophthalmology, San Francisco, CA. October 1999.